57975-93-6

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-Trifluoromethylphenyl)anthranilic acid is used as a key intermediate in the synthesis of pharmaceuticals for its potential biological activity. It contributes to the development of new drugs that can address various health conditions.
Used in Agrochemical Industry:
In the agrochemical industry, N-(4-Trifluoromethylphenyl)anthranilic acid serves as an essential component in the production of agrochemicals, helping to create effective solutions for agricultural applications.
Used in Fine Chemicals Industry:
This chemical compound is utilized as an intermediate in the synthesis of fine chemicals, which are high-purity chemicals used in various applications, including research, pharmaceuticals, and specialty industries.
Used in Dyes and Pigments Production:
N-(4-Trifluoromethylphenyl)anthranilic acid is used as an intermediate in the production of dyes and pigments, contributing to the creation of vibrant colors and shades for various industries, such as textiles, plastics, and printing inks.
Used in Anti-inflammatory and Analgesic Applications:
Due to its potential biological activity, N-(4-Trifluoromethylphenyl)anthranilic acid has been studied for its anti-inflammatory and analgesic properties, making it a promising candidate for the development of new treatments for pain and inflammation-related conditions.

InChI:InChI=1/C14H10F3NO2/c15-14(16,17)9-5-7-10(8-6-9)18-12-4-2-1-3-11(12)13(19)20/h1-8,18H,(H,19,20)

Upstream product

• 134-20-3 2-carbomethoxyaniline 
• 455-14-1 4-trifluoromethylphenylamine 
• 88-67-5 2-Iodobenzoic acid 
• 455-13-0 4-Iodobenzotrifluoride 

Downstream Products

• 13481-63-5 SKF-32802 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma

COX-2 and STAT3 are two key culprits in the glioma microenvironment. Herein, to inhibit COX-2 and block STAT3 signaling, we disclosed 27 N-anthraniloyl tryptamine compounds based on the combination of melatonin derivatives and N-substituted anthranilic acid derivatives. Among them, NP16 showed the best antiproliferative activity and moderate COX-2 inhibition. Of note, NP16 decreased the level of p-JAK2 and p-STAT3, and blocked the nuclear translocation of STAT3 in GBM cell lines. Moreover, NP16 downregulated the MMP-9 expression of BV2 cells in a co-culture system of BV2 and C6 glioma cells, abrogated the proliferative/invasive/migratory abilities of GBM cells, induced apoptosis by ROS and the Bcl-2-regulated apoptotic pathway, and induced obvious G2/M arrest in glioma cells in vitro. Furthermore, NP16 displayed favorable pharmacokinetic profiles covering long half-life (11.43 ± 0.43 h) and high blood-brain barrier permeability. Finally, NP16 effectively inhibited tumor growth, promoted the survival rate, increased the expression of E-cadherin and reduced overproduction of PGE2, MMP-9, VEGF-A and the level of p-STAT3 in tumor tissue, and improved the anxiety-like behavior in C6 glioma model. All these evidences demonstrated N-anthraniloyl tryptamine derivatives as multifunctional anti-glioma agents with high potency could drain the swamp to beat glioma.

OXADIAZOLE COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME

The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the intracellular chloride channel inhibition and method of screening a chloride channel blocking agent.

Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors

Eight small molecules were synthesized to evaluate the structure activity relationships (SAR) of N-substituted anthranilic acids. The molecules were synthesized by benzylation or arylation of methyl anthranilate. A light scattering-based amyloid fibril formation assay was used to evaluate potential inhibitors of transthyretin (TTR) amyloid fibril formation in vitro. The m-carboxyphenylated and o-trifluoromethylphenylated anthranilic acids are potent inhibitors that will be subjected to further SAR and structural analysis.